{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:10:42Z","timestamp":1740107442024,"version":"3.37.3"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,7,17]],"date-time":"2023-07-17T00:00:00Z","timestamp":1689552000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,7,17]],"date-time":"2023-07-17T00:00:00Z","timestamp":1689552000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["22K06718"],"award-info":[{"award-number":["22K06718"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1007\/s00280-023-04568-x","type":"journal-article","created":{"date-parts":[[2023,7,17]],"date-time":"2023-07-17T06:02:24Z","timestamp":1689573744000},"page":"271-278","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effect of massive ascites on ramucirumab pharmacokinetics in patients with gastrointestinal cancers: a population pharmacokinetic analysis"],"prefix":"10.1007","volume":"92","author":[{"given":"Takuya","family":"Kaneko","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2497-0063","authenticated-orcid":false,"given":"Kosuke","family":"Doki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiyuki","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshikazu","family":"Moriwaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiharu","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masato","family":"Homma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,7,17]]},"reference":[{"key":"4568_CR1","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(13)61719-5","volume":"383","author":"CS Fuchs","year":"2014","unstructured":"Fuchs CS, Tomasek J, Yong CJ et al (2014) Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 383:31\u201339. https:\/\/doi.org\/10.1016\/S0140-6736(13)61719-5","journal-title":"Lancet"},{"key":"4568_CR2","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1016\/S1470-2045(14)70420-6","volume":"15","author":"H Wilke","year":"2014","unstructured":"Wilke H, Muro K, Van Cutsem E et al (2014) Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol 15:1224\u20131235. https:\/\/doi.org\/10.1016\/S1470-2045(14)70420-6","journal-title":"Lancet Oncol"},{"key":"4568_CR3","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.2217\/fon-2022-0281","volume":"18","author":"S Iwasa","year":"2022","unstructured":"Iwasa S, Bando H, Piao Y et al (2022) The clinical position of ramucirumab-containing regimens for advanced gastric cancer: a review of clinical trial data. Futur Oncol 18:2709\u20132721. https:\/\/doi.org\/10.2217\/fon-2022-0281","journal-title":"Futur Oncol"},{"key":"4568_CR4","unstructured":"European medicines agency (EMA) (2022) Cyramza-epar product information. http:\/\/www.ema.europa.eu. Accessed 4 Mar, 2023"},{"key":"4568_CR5","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1158\/1535-7163.MCT-16-0895","volume":"16","author":"J Tabernero","year":"2017","unstructured":"Tabernero J, Ohtsu A, Muro K et al (2017) Exposure-response analyses of ramucirumab from two randomized, phase III trials of second-line treatment for advanced gastric or gastroesophageal junction cancer. Mol Cancer Ther 16:2215\u20132223. https:\/\/doi.org\/10.1158\/1535-7163.MCT-16-0895","journal-title":"Mol Cancer Ther"},{"key":"4568_CR6","doi-asserted-by":"publisher","first-page":"2741","DOI":"10.1111\/bcp.13403","volume":"83","author":"L O\u2019Brien","year":"2017","unstructured":"O\u2019Brien L, Westwood P, Gao L, Heathman M (2017) Population pharmacokinetic meta-analysis of ramucirumab in cancer patients. Br J Clin Pharmacol 83:2741\u20132751. https:\/\/doi.org\/10.1111\/bcp.13403","journal-title":"Br J Clin Pharmacol"},{"key":"4568_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10147-012-0396-6","volume":"18","author":"E Cavazzoni","year":"2013","unstructured":"Cavazzoni E, Bugiantella W, Graziosi L et al (2013) Malignant ascites: pathophysiology and treatment. Int J Clin Oncol 18:1\u20139. https:\/\/doi.org\/10.1007\/s10147-012-0396-6","journal-title":"Int J Clin Oncol"},{"key":"4568_CR8","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.ejca.2005.11.018","volume":"42","author":"G Becker","year":"2006","unstructured":"Becker G, Galandi D, Blum HE (2006) Malignant ascites: systematic review and guideline for treatment. Eur J Cancer 42:589\u2013597. https:\/\/doi.org\/10.1016\/j.ejca.2005.11.018","journal-title":"Eur J Cancer"},{"key":"4568_CR9","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1097\/FTD.0000000000000926","volume":"43","author":"T Kaneko","year":"2021","unstructured":"Kaneko T, Doki K, Yamada T et al (2021) Bevacizumab distribution into ascitic fluid decreases serum drug exposure. Ther Drug Monit 43:813\u2013814. https:\/\/doi.org\/10.1097\/FTD.0000000000000926","journal-title":"Ther Drug Monit"},{"key":"4568_CR10","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s00280-022-04479-3","volume":"90","author":"T Kaneko","year":"2022","unstructured":"Kaneko T, Doki K, Yamada T et al (2022) Distribution of therapeutic monoclonal antibodies into ascites in advanced gastric cancer patients with peritoneal metastasis: case reports and literature review. Cancer Chemother Pharmacol 90:421\u2013426. https:\/\/doi.org\/10.1007\/s00280-022-04479-3","journal-title":"Cancer Chemother Pharmacol"},{"key":"4568_CR11","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s12885-018-4057-7","volume":"18","author":"H Matsumoto","year":"2018","unstructured":"Matsumoto H, Kawazoe A, Shimada K et al (2018) A retrospective study of the safety and efficacy of paclitaxel plus ramucirumab in patients with advanced or recurrent gastric cancer with ascites. BMC Cancer 18:120. https:\/\/doi.org\/10.1186\/s12885-018-4057-7","journal-title":"BMC Cancer"},{"key":"4568_CR12","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s10120-020-01043-x","volume":"23","author":"TE Nakajima","year":"2020","unstructured":"Nakajima TE, Yamaguchi K, Boku N et al (2020) Randomized phase II\/III study of 5-fluorouracil\/l-leucovorin versus 5-fluorouracil\/l-leucovorin plus paclitaxel administered to patients with severe peritoneal metastases of gastric cancer (JCOG1108\/WJOG7312G). Gastric Cancer 23:677\u2013688. https:\/\/doi.org\/10.1007\/s10120-020-01043-x","journal-title":"Gastric Cancer"},{"key":"4568_CR13","doi-asserted-by":"publisher","first-page":"abstr121","DOI":"10.1200\/jco.2015.33.3_suppl.121","volume":"33","author":"J Tabernero","year":"2015","unstructured":"Tabernero J, Ohtsu A, Muro K et al (2015) Exposure-response (E-R) relationship of ramucirumab (RAM) from two global, randomized, double-blind, phase 3 studies of patients (Pts) with advanced second-line gastric cancer. J Clin Oncol 33:abstr121. https:\/\/doi.org\/10.1200\/jco.2015.33.3_suppl.121","journal-title":"J Clin Oncol"},{"key":"4568_CR14","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1007\/s10120-017-0737-2","volume":"21","author":"TY Kim","year":"2018","unstructured":"Kim TY, Yen CJ, Al-Batran SE et al (2018) Exposure\u2013response relationship of ramucirumab in East Asian patients from RAINBOW: a randomized clinical trial in second-line treatment of gastric cancer. Gastric Cancer 21:276\u2013284. https:\/\/doi.org\/10.1007\/s10120-017-0737-2","journal-title":"Gastric Cancer"},{"key":"4568_CR15","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s00280-017-3380-z","volume":"80","author":"AL Cohn","year":"2017","unstructured":"Cohn AL, Yoshino T, Heinemann V et al (2017) Exposure\u2013response relationship of ramucirumab in patients with advanced second-line colorectal cancer: exploratory analysis of the RAISE trial. Cancer Chemother Pharmacol 80:599\u2013608. https:\/\/doi.org\/10.1007\/s00280-017-3380-z","journal-title":"Cancer Chemother Pharmacol"},{"key":"4568_CR16","doi-asserted-by":"publisher","first-page":"3182","DOI":"10.1111\/bcp.15233","volume":"88","author":"R de Wit","year":"2022","unstructured":"de Wit R, Powles T, Castellano D et al (2022) Exposure-response relationship of ramucirumab in RANGE, a randomized phase III trial in advanced urothelial carcinoma refractory to platinum therapy. Br J Clin Pharmacol 88:3182\u20133192. https:\/\/doi.org\/10.1111\/bcp.15233","journal-title":"Br J Clin Pharmacol"},{"key":"4568_CR17","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s00280-018-3560-5","volume":"82","author":"EF Smit","year":"2018","unstructured":"Smit EF, Garon EB, Reck M et al (2018) Exposure\u2013response relationship for ramucirumab from the randomized, double-blind, phase 3 REVEL trial (docetaxel versus docetaxel plus ramucirumab) in second-line treatment of metastatic non-small cell lung cancer. Cancer Chemother Pharmacol 82:77\u201386. https:\/\/doi.org\/10.1007\/s00280-018-3560-5","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-023-04568-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-023-04568-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-023-04568-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T02:02:35Z","timestamp":1692324155000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-023-04568-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,17]]},"references-count":17,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["4568"],"URL":"https:\/\/doi.org\/10.1007\/s00280-023-04568-x","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"type":"print","value":"0344-5704"},{"type":"electronic","value":"1432-0843"}],"subject":[],"published":{"date-parts":[[2023,7,17]]},"assertion":[{"value":"6 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Ethics Committee of University of Tsukuba Hospital (ethical approval No. R01-343).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent to participate was obtained from all patients.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}